CombiMatrix Enters into Distribution Agreement with Singapore-Based Cell Sciences; Cell Sciences to Distribute Arrays Including CombiMatrix's New Influenza Array.NEWPORT BEACH Newport Beach, residential and resort city (1990 pop. 66,643), Orange co., S Calif., on Newport Bay and the Pacific Ocean; inc. 1906. It is a popular seaside resort and yachting center. Manufactures include electrical and medical equipment, computers, boats, and adhesives. , Calif. -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ) announced today that its CombiMatrix group has entered into a non-exclusive distribution agreement with Cell Sciences Pte Ltd, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of the CyGenics Group, to distribute CombiMatrix products and services in Singapore, Malaysia, Thailand, Philippines, Hong Kong, and Indonesia. Under the terms of the agreement, Cell Sciences will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza Research Microarray. "We are very pleased to have expanded our distribution network into South East Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share." "Cell Sciences has identified CombiMatrix's platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Dr. John Khong, Vice President & General Manager, Cell Sciences. "This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship. In addition, we are impressed with CombiMatrix's recently launched influenza array. As we enter the flu season, and focus on H5N1 intensifies, we anticipate increased interest in this array." ABOUT CELL SCIENCES Cell Sciences is a subsidiary of CyGenics which is listed in the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. (ASX ASX See: Australian Stock Exchange ). It has an established network covering Singapore, Malaysia, Thailand, Indonesia, Philippines, Hong Kong, China, Australia and USA. Cell Sciences is a supplier of diagnostics for life science research and manufactures proprietary products. Cell Sciences drives the sales, marketing and distribution for biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products. In Jan 2004, the company launched a patented 3-D growth scaffold and the market's first disposable cell culture spinner systems. Cell Sciences markets products targeting an extensive customer base comprising laboratories (research, clinical and bioprocessing), industry (biopharmaceuticals), specialists and hospitals. The company focuses on product lines core to the strategic business of the CyGenics Group in areas of stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. biotechnology and regenerative medicines, as well as products that add to a more comprehensive offering to the customers we serve. Visit us at www.cygenics.com/cellsciences. ABOUT CYGENICS CyGenics is a cell therapy company focused on the development and commercialization of adult stem cell-related technologies and applications into therapeutic products and services. From its headquarters in Australia, CyGenics operates four subsidiary businesses: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), Cytomatrix (cell therapeutics and technology development) based in the USA, and CytoVations (new product development) also based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN CYN Canyon . For more information, please visit www.cygenics.com. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group. The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 34 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency co·her·en·cy n. pl. co·her·en·cies Coherence. Noun 1. coherency - the state of cohering or sticking together coherence, cohesion, cohesiveness , credit card fraud Credit card fraud is a wide-ranging term for theft and fraud committed using a credit card or any similar payment mechanism as a fraudulent source of funds in a transaction. The purpose may be to obtain goods without paying, or to obtain unauthorized funds from an account. protection, database management, data encryption & product activation, digital media transmission (DMT See DSL. (R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS See eComStation. , interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion